Composition and method for treating metabolic disorders
Bromocriptine citrate administered to a vertebrate, animal or human, can be used for any purpose including, e.g., the long-term modification and regulation of metabolic disorders, including prediabetes, obesity, insulin resistance, hyperinsulinemia, hyperglycemia and type 2 diabetes mellitus (T2DM) and/or, e.g., the treatment of other medical disorder(s) including immune or endocrine disorders or diseases. Bromocriptine citrate is administered over a limited or extended period at a time of day dependent on re-establishing the normal circadian rhythm of central dopaminergic activity of healthy members of a similar species and sex. Insulin resistance, hyperinsulinemia and hyperglycemia, T2DM, prediabetes, MS or all, can be controlled in humans on a long term basis by such treatment inasmuch as the daily administration of bromocriptine citrate resets neuronal activity timing in the neural centers of the brain to produce long term effects.
1. A method of treating non-alcoholic steatohepatitis(NASH) which comprises administering to a patient suffering from NASH a pharmaceutical composition comprising bromocriptine citrate at a time of day that will increase central dopaminergic activity of the patient at the time of day of the circadian peak of central dopaminergic activity in a healthy individual of the same species and sex.
2. The method of claim 1 wherein the time of day is between 0400 and 1200 hours of the day.
3. The method of claim 2 wherein the pharmaceutical composition comprises a tablet.
4. The method of claim 2 wherein the tablet comprises a sublingual tablet.
5. The method of claim 1 wherein the pharmaceutical composition comprises a nasal spray.
6. The method of claim 2 wherein the pharmaceutical composition comprises a solution.
7. The method of claim 2 wherein the pharmaceutical composition comprises a capsule.
8. The method of claim 2 wherein the pharmaceutical composition comprises a nasal spray.
9. The method of claim 2 which comprises orally administering the pharmaceutical composition.
10. The method of claim 2 which comprises nasally administering the pharmaceutical composition.
11. The method of claim 2 which comprises administering the pharmaceutical composition as an aerosol.
12. The method of claim 2 which comprises administering the pharmaceutical composition via the sublingual route.
13. The method of claim 2 which comprises transdermally administering the pharmaceutical composition.
14. The method of claim 2 which comprises buccally administering the pharmaceutical composition.
15. The method of claim 2 which comprises subcutaneously administering the pharmaceutical composition.
16. The method of claim 2 which comprises sublingually administering the pharmaceutical composition.
17. The method of claim 2 wherein the time of day is within two hours after awakening.
18. The method of claim 2 wherein the time of day is between 4 hours before and four hours after the onset of daily locomotor activity.
19. The method of claim 1 wherein the time of day is between two hours before and two hours after the onset of daily locomotor activity.
20. The method of claim 1 which comprises administering the bromocriptine citrate with one or more pharmaceutically acceptable excipients.
21. The method of claim 1 which comprises administering the bromocriptine citrate in an oral dosage form.
22. The method of claim 1 which comprises parenterally administering the bromocriptine citrate.
23. The method of claim 1 which comprises co-administering at least one of an alpha-I adrenergic antagonist, an alpha 2 adrenergic agonist, a serotonergic inhibitor or a serotonin 5HT 1b agonist with the bromocriptine citrate.
24. The method of claim 1 which comprises daily administration of the bromocriptine citrate.
25. The method of claim 1 which comprises administering the bromocriptine citrate and additionally administering a peripheral acting agent that is a member selected from the group consisting of an anti-hypertensive agent, anti-diabetes agent, or HMGCoA reductase inhibitors.
26. The method of claim 1 which comprises administering the bromocriptine citrate with insulin or a postprandial insulin secretogogue.
27. A method of treating non-alcoholic steatohepatitis (NASH) which comprises administering to a patient suffering from NASH a pharmaceutical composition comprising bromocriptine citrate at a time of day that will increase central dopaminergic activity of the patient at the time of day of the circadian peak of central dopaminergic activity in a healthy individual of the same species and sex and administering the composition together with a dopamine D1 agonist.
28. The method of claim 26 wherein the dopamine D1 agonist is selected from the group consisting of SKF-3893, SKF-82958 or SKF-89327.
29. The method of claim 19 wherein the pharmaceutical composition has a total weight of between about 2 mg and about 2000 mg.
30. A method of treating non-alcoholic steatohepatitis(NASH) which comprises administering to a patient suffering from NASH a pharmaceutical composition comprising bromocriptine citrate within 4 hours of waking in the morning.
31. The method of treating non-alcoholic steatohepatitis (NASH) which comprises administering bromocriptine citrate to a patient in need of such treatment at a time of day that will increase central dopaminergic activity of the patient within four hours of the circadian peak of central dopaminergic activity in a healthy individual of the same species and sex.
32. The method of treating non-alcoholic steatohepatitis (NASH) comprising orally administering to a patient suffering from NASH a pharmaceutical composition comprising between about 0.05 μg and 0.5 mg/kg of body weight per day of bromocriptine citrate administered to the patient between 0400 and 1200 hours of the day.